Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-3.15% $1.230
America/New_York / 19 apr 2024 @ 13:01
FUNDAMENTALS | |
---|---|
MarketCap: | 110.61 mill |
EPS: | -2.11 |
P/E: | -0.580 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 89.93 mill |
Avg Daily Volume: | 0.625 mill |
RATING 2024-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.580 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.580 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.023 (-16.83%) $-0.207 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 1.145 - 1.315 ( +/- 6.91%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Howson Tamar D | Buy | 64 959 | Stock Option |
2024-03-04 | Howson Tamar D | Sell | 10 000 | Stock Option |
2024-03-04 | Howson Tamar D | Sell | 10 000 | Stock Option |
2024-03-04 | Howson Tamar D | Sell | 9 986 | Stock Option |
2024-03-04 | Howson Tamar D | Sell | 15 000 | Stock Option |
INSIDER POWER |
---|
44.67 |
Last 97 transactions |
Buy: 5 390 136 | Sell: 1 509 904 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.230 (-3.15% ) |
Volume | 0.163 mill |
Avg. Vol. | 0.625 mill |
% of Avg. Vol | 26.02 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.235 | N/A | Active |
---|
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.